Boston Scientific Corporation $BSX Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC cut its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 5.8% in the 3rd quarter, HoldingsChannel reports. The fund owned 246,502 shares of the medical equipment provider’s stock after selling 15,052 shares during the quarter. ProShare Advisors LLC’s holdings in Boston Scientific were worth $10,760,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of BSX. Avantax Planning Partners Inc. lifted its position in Boston Scientific by 4.0% in the first quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider’s stock valued at $329,000 after purchasing an additional 201 shares during the last quarter. WPG Advisers LLC boosted its stake in shares of Boston Scientific by 11.9% during the first quarter. WPG Advisers LLC now owns 1,916 shares of the medical equipment provider’s stock valued at $120,000 after purchasing an additional 203 shares during the period. Natural Investments LLC grew its holdings in shares of Boston Scientific by 1.3% in the second quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock worth $685,000 after purchasing an additional 206 shares during the last quarter. 180 Wealth Advisors LLC grew its holdings in shares of Boston Scientific by 3.6% in the first quarter. 180 Wealth Advisors LLC now owns 6,468 shares of the medical equipment provider’s stock worth $406,000 after purchasing an additional 223 shares during the last quarter. Finally, MGO One Seven LLC grew its holdings in shares of Boston Scientific by 1.9% in the third quarter. MGO One Seven LLC now owns 14,061 shares of the medical equipment provider’s stock worth $614,000 after purchasing an additional 260 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported that the SIMPLAAFY trial of its WATCHMAN FLX Pro heart device met its six-month primary endpoints. The results found two post-implant drug regimens non-inferior to dual-antiplatelet therapy, potentially supporting simpler treatment after the procedure. Article: SIMPLAAFY study results
• Neutral Sentiment: Boston Scientific and Blackstone Life Sciences announced a $455 million collaboration to co-develop the VITALYST heart-pump technology. The arrangement may ease near-term development costs, but an analyst noted it could defer growth and leave longer-term uncertainty. Article: VITALYST collaboration Article: Analyst assessment of VITALYST deal
• Negative Sentiment: A Zacks analysis flagged weakening earnings estimates, softer momentum in core businesses and major growth catalysts that may not arrive until 2028. Those concerns could overshadow the company’s valuation discount. Article: Valuation and earnings-growth analysis
• Negative Sentiment: J.P. Morgan maintained a Hold rating, while TD Cowen also cut its rating to Hold; Barclays lowered its price target. The cautious analyst stance adds to concerns about near-term growth. Article: J.P. Morgan rating Article: TD Cowen rating Article: Barclays price-target change

Boston Scientific Stock Performance

Shares of BSX opened at $43.58 on Wednesday. The business’s fifty day simple moving average is $44.55 and its two-hundred day simple moving average is $56.38. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 12 month low of $39.57 and a 12 month high of $105.65. The company has a market cap of $63.15 billion, a price-to-earnings ratio of 18.47, a P/E/G ratio of 1.29 and a beta of 0.60.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a return on equity of 18.73% and a net margin of 16.62%. The firm had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter in the previous year, the business earned $0.75 earnings per share. The company’s revenue was up 1.4% on a year-over-year basis. Research analysts anticipate that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BSX. Rothschild & Co Redburn lowered their price target on shares of Boston Scientific from $106.00 to $78.00 and set a “buy” rating for the company in a report on Thursday, July 30th. UBS Group reduced their price objective on shares of Boston Scientific from $67.00 to $57.00 and set a “buy” rating on the stock in a research report on Thursday, October 29th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Oppenheimer lowered shares of Boston Scientific from an “outperform” rating to a “market perform” rating in a research note on Thursday, October 29th. Finally, Citigroup reduced their price target on Boston Scientific from $48.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.43.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.